carbenoxolone sodium has been researched along with Hypoxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isaeva, EV; Lushnikova, IV; Lykhmus, OY; Patseva, MA; Savotchenko, AV; Skibo, GG; Skok, MV; Voytenko, LP | 1 |
| Benabou, S; de Pina-Benabou, MH; Federoff, HJ; Kyrozis, A; Rempe, D; Rozental, R; Spray, DC; Stanton, PK; Szostak, V; Urban-Maldonado, M; Uziel, D | 1 |
2 other study(ies) available for carbenoxolone sodium and Hypoxia
| Article | Year |
|---|---|
Hippocampal GABAergic interneurons coexpressing alpha7-nicotinic receptors and connexin-36 are able to improve neuronal viability under oxygen-glucose deprivation.
Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Animals, Newborn; Carbenoxolone; Connexins; GABA Antagonists; gamma-Aminobutyric Acid; Gap Junction delta-2 Protein; Gene Expression Regulation; Glucose; Glutamate Decarboxylase; Hippocampus; Hypoxia; In Vitro Techniques; Interneurons; Mefloquine; Mitochondria; Nicotinic Antagonists; Organ Culture Techniques; Patch-Clamp Techniques; Pyridazines; Rats; Rats, Wistar; Synaptic Transmission | 2015 |
Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia.
Topics: Animals; Anti-Ulcer Agents; Apoptosis; Brain; Carbenoxolone; Caspase 3; Caspases; Cell Communication; Connexins; Disease Models, Animal; DNA; Electrophysiology; Female; Gap Junctions; Glucose; Hippocampus; Hypoxia; Hypoxia-Ischemia, Brain; Ischemia; Male; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Nerve Degeneration; Neurons; Neuroprotective Agents; Nucleosomes; Oxygen; Polymerase Chain Reaction; Propidium; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors | 2005 |